IMTXW Projected Dividend Yield
Wt Exp 07/01/2025/Immatics NV ( NASDAQ : IMTXW )Immatics is a holding company. Through its subsidiaries, Co. is engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer patients. Co.'s focus is the generation of therapeutic options for solid tumor patients. Co. is developing its targeted immunotherapy product candidates via two treatment modalities: Adoptive Cell Therapies (ACT) and antibody-like Bispecifics. Co.'s clinical product class ACTengine is based on genetically modifying a patient's own T cells to express a proprietary TCR. Co.'s TCR Bispecifics are consisting of a portion of the TCR that recognizes cancer cells and a T cell recruiter domain that recruits and activates T cells. 20 YEAR PERFORMANCE RESULTS |
IMTXW Dividend History Detail IMTXW Dividend News IMTXW Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |